Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

95
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
95
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

109
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
109
Autoimmune Disorders01:29

Autoimmune Disorders

384
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
384
T Cell Types and Functions01:24

T Cell Types and Functions

945
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
945

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Intra-erosive Power Doppler Signals Detected by Musculoskeletal Ultrasound with 1-year Radiographic Progression in Early Rheumatoid Arthritis.

The Journal of rheumatology·2026
Same author

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Mediterranean journal of rheumatology·2026
Same author

Rethinking nailfold capillaroscopy in SSc: proposal for a novel binary classification of capillary changes based on severity.

Rheumatology (Oxford, England)·2026
Same author

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

Journal of psoriasis and psoriatic arthritis·2026
Same author

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same author

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: May 31, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.1K

Remote-Customized Telecontrol for Patients with Rheumatoid Arthritis: The iARPlus (Innovative Approach in

Fausto Salaffi1, Sonia Farah1, Eleonora Di Donato1

  • 1Rheumatology Unit, Università Politecnica delle Marche, "Carlo Urbani" Hospital, Via Aldo Moro, 25, 60035 Jesi, Italy.

Journal of Personalized Medicine
|January 24, 2025
PubMed
Summary

The Rheumatoid Arthritis Impact of Disease (RAID) score effectively monitors rheumatoid arthritis (RA) activity during teleconsultations. Janus kinase inhibitors (JAKis) showed better outcomes than adalimumab for RA patients.

Keywords:
RAIDdisease activityrheumatoid arthritistelecontrol

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:49

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

76
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.0K

Related Experiment Videos

Last Updated: May 31, 2025

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.1K
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:49

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

76
Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis
06:31

Author Spotlight: Enhancing Rheumatoid Arthritis Research Through HR-pQCT Imaging Analysis

Published on: October 6, 2023

2.0K

Area of Science:

  • Rheumatology
  • Digital Health
  • Patient-Reported Outcomes

Background:

  • Rheumatoid arthritis (RA) management benefits from enhanced patient monitoring.
  • Telecontrol strategies aim to improve patient outcomes in chronic disease management.

Purpose of the Study:

  • To assess the feasibility of using the Rheumatoid Arthritis Impact of Disease (RAID) score during teleconsultations for RA disease activity monitoring.
  • To evaluate the iARPlus web-based platform for remote RA management.

Main Methods:

  • A pilot study involving 40 RA patients over 12 months.
  • Utilized two in-person visits and seven teleconsultations via the iARPlus platform.
  • Measured disease activity using the Clinical Disease Activity Index (CDAI) and self-reported RAID scores.

Main Results:

  • Strong correlations observed between CDAI and RAID scores at baseline (ρ = 0.809) and follow-up (ρ = 0.789).
  • Patients treated with Janus kinase inhibitors (JAKis) demonstrated greater reductions in RAID scores and improved pain relief compared to adalimumab.
  • JAKi-treated patients exhibited higher rates of disease remission.

Conclusions:

  • The RAID score is effective for assessing RA disease activity in teleconsultation settings.
  • JAKi treatment appears more effective than adalimumab for pain control and disease activity in RA.
  • Further research is warranted to confirm the clinical and economic advantages of RA telecontrol.